linjc16/ctgov huggingface dataset:
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile

Study Overview
=================
Brief Summary
-----------------
This is an observational study looking at the characteristics of patients consulting for genital warts in the first semester 2010 at the public sexual health clinic of Valparaiso, Chile. The objectives are: to have an epidemiological profile, estimating cost of the disease for the health system and the patient and analyzing possible psychosocial consequences of the condition for the patients.

Official Title
-----------------
Genital Warts: Studies for Establishing Epidemiological Profile, Psychosocial Consequences and Costs of Disease in Attendants to the Sexual Health Clinic of the Public Health Service of Valparaiso and San Antonio, Chile.

Conditions
-----------------
Condylomata Acuminata

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women 18 years of age or older Having being diagnosed with genital warts Consulting the sexual health clinic only for genital warts Patients accepting to be included in the study Exclusion Criteria: Immunodeficiency HIV positive Having being diagnosed with cancer or pre-cancerous lesions Pregnancy Presenting a sexual transmissible infection other than genital warts.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Genital warts treated<br>Patients that have had treatment on their genital warts | |
| Genital warts on treatment<br>Patients currently being treated for genital warts | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with altered psychosocial tests as a Measure of impact of presenting genital warts. | The psychosocial consequences of presenting genital warts will be assessed. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genital warts
Standard Deviation of the Distance Between the Sural Nerve and Achilles Tendon by Ultrasound

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to define the standardization of the distance between the Sural nerve & Achilles tendon, in otherwise healthy persons and athletes.

Detailed Description
-----------------
The distance between the two anatomic structures is measured by US and data is analyzed to define the standardized distance in the population in order to avoid damage to the sural nerve while repairing an Achilles tendon rupture using the percutaneous methode.

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy age 18-60 Exclusion Criteria: known bone or muscle disease major trauma to the leg or ankle in present or past surgery of leg or ankle in the past mental disabilities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| otherwise healthy persons<br>healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| distance between the Sural nerve & the Achilles tendon | one time measurment of the distance between the sural nerve & the Achilles tendon, using an US device. | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
achilles tendon, sural nerve, distance, US, ultrasound, Distance between Sural nerve and the Achilles tendon
Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits

Study Overview
=================
Brief Summary
-----------------
Epilepsy is a frequent neurological disease in childhood, characterized by recurrent seizures and sometimes with major effects on social, behavioral and cognitive development. Childhood focal epilepsies particularly are age-related diseases mainly occurring during developmental critical period. A complex interplay between brain development and maturation processes and susceptibility genes may contribute to the development of various childhood epileptic syndromes associated with language and cognitive deficits. Indeed, the Landau-Kleffner syndrome (LKS), the continuous spike-and-waves during sleep syndrome (CSWS), and the benign childhood epilepsy with centrotemporal spikes (BCECTS) or benign rolandic epilepsy, are different syndromes that are considered as part of a single continuous spectrum of disorders. While genetic component in those three syndromes remains elusive, novel and high throughput genome analyzes could bring interesting insights into the possible genetic defects and pathophysiological mechanisms underlying and linking the various disorders associating epilepsy with speech and cognitive impairments.

Official Title
-----------------
Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Genetic: genome analyzes (genetic defects and pathophysiological mechanisms )


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: iodiopathic focal epilepsy with cognitif deficit Exclusion Criteria: medical history of status epilepticus

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: genome analyzes (genetic defects and pathophysiological mechanisms )|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benign childhood epilepsy
Laparoscopic Sacrocolpopexy: Long Term Follow-up

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the long term results of laparoscopic sacrocolpopexy regarding anatomical results, recurrences, complications, further surgeries required, patients satisfaction and quality of life.

Official Title
-----------------
Laparoscopic Sacrocolpopexy: Long Term Results With Special Focus on Anatomical Results and Quality of Life

Conditions
-----------------
Vaginal Vault Prolapse

Intervention / Treatment
-----------------
* Other: Examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients operated for vaginal vault prolapse at our institution by laparoscopic sacrocolpopexy between 2003 and 2007 consent Exclusion Criteria: no consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Operated by laparoscopic sacrocolpopexy<br>Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007 | Other: Examination<br>* Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system<br>* Other names: assessment;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrences according to pelvic organ prolapse quantification (POP-Q) assessment | Recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system | 3-6 years after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | Quality of life as assessed by a specific validated questionnaire | 3-6 years after surgery |
Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Study Overview
=================
Brief Summary
-----------------
This research investigates the use of autologous bone marrow stem cells for the treatment of medically refractory temporal lobe epilepsy patients.

Detailed Description
-----------------
The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for patients with temporal lobe refractory epilepsy. We are mainly evaluating seizure frequency, hippocampal volume an cognitive performance

Official Title
-----------------
Phase 1 Study of Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Procedure: Stem cell transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: temporal lobe medically refractory epilepsy patients with hippocampal atrophy Exclusion Criteria: under 18 or over 65 years old patients previous neurological surgery other neurodegenerative diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: stem cell transplantation<br>Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control. | Procedure: Stem cell transplantation<br>* Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography<br>* Other names: BMMSC - Bone Marrow Mononuclear Stem Cells;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| seizure frequency |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse effects |  | 6 months | 
| hippocampal volume |  | 6 months | 
| cognitive performance |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Seizure frequency, Hippocampal volume, Adverse effects
Ultrasound-guided PENG Block for Shoulder Surgery

Study Overview
=================
Brief Summary
-----------------
Significant pain after shoulder surgery induce worse experience and may delay recovery of patients undergoing shoulder surgery. Interscalene brachial plexus block (ISB) is a common and rapid-onset procedure for pain control of patients undergoing shoulder surgery. However, the high incidence of adverse events such as hemidiaphragmatic paresis, horner syndrome after interscalene block threatened patients' safety and raised clinicians' concerns on them. Hence, effective analgesia alternatives to interscalene block with less complications are needed. Recently, pericapsular Nerve Group (PENG) Block, a new technology is reported for block of articular branches of the shoulder and well pericapsular spread around the glenohumeral joint. In this study, we assume that PENG Block may offer a noinferior analgesia and less incidence of nerve block related adverse events compared with ISB.

Official Title
-----------------
Efficacy and Safety of Pericapsular Nerve Group (PENG) Block for Patients Undergoing Shoulder Surgery

Conditions
-----------------
Pain After Shoulder Surgery

Intervention / Treatment
-----------------
* Procedure: Pericapsular nerve group block
* Procedure: Interscalene block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III 18 years and older Shoulder surgery Exclusion Criteria: Severe pulmonary diseas Chronic pain disorders Infection of shouler skin Pregnant women Patients allergy to local anesthetics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br> | Procedure: Pericapsular nerve group block<br>* A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.<br>|
| Active Comparator: Group B<br> | Procedure: Interscalene block<br>* A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain scores | Pain after the shoulder surgery will be measured using an 11-point numerical rating scale (0 = no pain, 10 = worst pain imaginable). | 3 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  | 3 month |
Social Functioning in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
There are two research purposes of this study. One is to explore which psychosocial issue or biological issue would affect the social function among people with schizophrenia. The other one is to explore which social function would affect the job tenure among people with schizophrenia. There are 60 participants diagnosed with schizophrenia and divided into two groups, employment and unemployment. we will use several social function tests to collect social function, PANSS to evaluate their psychotic symptoms. And then we will compare and analysis the data through statistic software. Finally, we will have he answer about how social skills affect the social function and which social skill would affect the job tenure among people with schizophrenia.

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: schizophrenia Exclusion Criteria: substance abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1: employment<br> | |
| 2: unemployment<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of the probiotic use in patients with periampullary cancers undergone curative or palliative treatment considering nutritional status, postoperative complications, infection rate, length of hospitalization and mortality.

Official Title
-----------------
Effect of the Probiotics Use in Patients Undergoing Surgery for Periampullary Neoplasia - A Randomized Clinical Trial

Conditions
-----------------
Periampullary Carcinoma Nos

Intervention / Treatment
-----------------
* Dietary Supplement: Probiotics
* Dietary Supplement: Sugar pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in need of surgery for periampullary cancer Exclusion Criteria: Patients submitted to periampullary surgery without pathologic confirmation of cancer Patients unwilling to be a part of the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Sugar pill<br>The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period. | Dietary Supplement: Sugar pill<br> <br> |
| Active Comparator: Probiotics<br>The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery. | Dietary Supplement: Probiotics<br>* The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death will be considered as the primary outcome related to complications of surgical treatment in postoperative period | participants will be followed for the duration of hospital stay, an expected average of 15 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative infection rate | To assess postoperative infection rate in patients submitted to periampullary cancer surgery using probiotics. | participants will be followed for the duration of hospital stay, an expected average of 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Periampullary cancer, Surgery, Dietary supplementation, Nutritional assessment
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

Study Overview
=================
Brief Summary
-----------------
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

Official Title
-----------------
A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.

Conditions
-----------------
Peanut Allergy

Intervention / Treatment
-----------------
* Biological: Viaskin Peanut 250 mcg
* Biological: Viaskin Peanut 100 mcg
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Male or female from 1-3 years of age; Physician-diagnosed peanut allergy; Peanut-specific IgE level > 0.7 kU/L; Positive peanut SPT with a largest wheal diameter ≥ 6 mm; Positive DBPCFC at ≤ 300 mg peanut protein; Key Exclusion Criteria: Uncontrolled asthma; History of severe anaphylaxis to peanut; Prior immunotherapy to any food or other immunotherapy; Generalized severe dermatologic disease;

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Viaskin Peanut 250 mcg<br> | Biological: Viaskin Peanut 250 mcg<br>* Viaskin Peanut 250 mcg, once daily<br>|
| Experimental: Viaskin Peanut 100 mcg<br> | Biological: Viaskin Peanut 100 mcg<br>* Viaskin Peanut 100 mcg, once daily<br>|
| Placebo Comparator: Placebo<br> | Biological: Placebo<br>* Placebo patch, once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences between the percentage of treatment responders in the selected active Viaskin Peanut group compared to the placebo group. |  | Month 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EPIT, Epicutaneous, Immunotherapy, Viaskin
Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Study Overview
=================
Brief Summary
-----------------
response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

Detailed Description
-----------------
Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.

Official Title
-----------------
Treatment of Patient With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before Under and After Radiation and With Adding Cetuximab to K_RAS Wild-type Patients.

Conditions
-----------------
Rectum Cancer

Intervention / Treatment
-----------------
* Drug: cetuximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: advanced rectum cancer Exclusion Criteria: prior radiation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Capecitabine, oxaliplatin<br> | Drug: cetuximab<br>* cetuximab 500mg per meter square every second week<br>|
| Active Comparator: capecitabine, oxaliplatin and cetuximab<br>capecitabine, oxaliplatin ane cetuximab | Drug: cetuximab<br>* cetuximab 500mg per meter square every second week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response rate |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cetuximab, rectum cancer, radiation, MRI